---
provider: perplexity
model: sonar-deep-research
cached: false
start_time: '2026-11-06T15:54:19.008981'
end_time: '2026-11-06T16:01:31.089684'
duration_seconds: 432.08
template_file: templates/disease_pathophysiology_research.md
template_sha: "f452f0a9c7e3536175154b9683c45663f686f283"
template_variables:
  disease_name: Neurodevelopmental Disorder with Epilepsy and Brain Atrophy
  mondo_id: MONDO:0859265
  category: Mendelian
  causal_genes: ATP6V0A1
  omim_id: OMIM:619971
  synonyms: NEDEBA; ATP6V0A1-related neurodevelopmental disorder
provider_config:
  timeout: null
  max_retries: 3
  parameters:
    allowed_domains: []
    reasoning_effort: medium
    search_domain_filter: []
    return_citations: true
    temperature: 0.0
citation_count: 17
reference_validation:
  total_references: 3
  verified: 3
  not_found: 0
  unverifiable: 0
  confabulation_rate: 0.0
  relevance_assessed: 3
  on_topic: 2
  validator_version: 0.5.1
term_validation:
  total_terms: 37
  verified: 36
  not_found: 0
  obsolete: 0
  unverifiable: 1
  confabulation_rate: 0.0
  labels_checked: 25
  labels_matching: 18
  labels_mismatched: 4
  mislabelled_terms:
  - term_id: GO:0048761
    reported_labels:
    - ER to Golgi vesicle-mediated transport
    ontology_label: collenchyma cell differentiation
  - term_id: CL:0000679
    reported_labels:
    - cortical pyramidal neuron
    - pyramidal neuron
    ontology_label: glutamatergic neuron
  - term_id: UBERON:0003051
    reported_labels:
    - cerebral cortex layer
    ontology_label: ear vesicle
  - term_id: UBERON:0002038
    reported_labels:
    - cerebellar cortex
    ontology_label: substantia nigra
  labels_variant: 3
  needs_review: true
  adapter: 'ols:'
  validator_version: 0.4.5
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Neurodevelopmental Disorder with Epilepsy and Brain Atrophy
- **MONDO ID:** MONDO:0859265 (if available)
- **Causal gene(s):** ATP6V0A1
- **OMIM:** OMIM:619971
- **Synonyms:** NEDEBA; ATP6V0A1-related neurodevelopmental disorder
- **Category:** Mendelian

Many disease names are serial numbers ("... autosomal dominant 64", "... 26") that
do not say which gene the disease is about, and a similarly named disease with a
different gene is easy to research by mistake. Research the disease with the MONDO
ID and causal gene given above, and name its causal gene in your first paragraph.
If the name seems to point to a different gene or OMIM entry, follow the
identifiers above.

## Research Objectives

Please provide a comprehensive research report on **Neurodevelopmental Disorder with Epilepsy and Brain Atrophy** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

**Present this section as an ordered causal chain first, then the detail below.**
Open with a numbered sequence of mechanistic steps running from the initiating
lesion (mutation, exposure, infection) to the clinical manifestation, one step per
line, each naming what it causes next. State the causal verb explicitly ("leads
to", "results in") and say where a step is inferred rather than demonstrated.
Where the mechanism branches, show the branch. The categories below are a
checklist of what to cover within those steps, not the organizing structure —
a step may draw on several of them, and a category may contribute to several
steps.

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

# Neurodevelopmental Disorder with Epilepsy and Brain Atrophy (NEDEBA) Caused by ATP6V0A1 Variants

Neurodevelopmental disorder with epilepsy and brain atrophy is a rare autosomal recessive Mendelian disease caused by biallelic pathogenic variants in **ATP6V0A1**, which encodes the neuron-enriched a1 subunit of the V0 domain of the vacuolar H\(^+\)-ATPase (V-ATPase).\[6\][13\][14\] This disorder, also referred to as **NEDEBA** and catalogued in OMIM as 619971, is characterized clinically by early-onset progressive myoclonus epilepsy, ataxia, global developmental delay, and progressive cerebral and cerebellar atrophy on neuroimaging, with a natural history of severe, progressive neurological disability.\[9\][10\][14\][17\] At the molecular level, ATP6V0A1-related NEDEBA reflects loss-of-function of the V-ATPase proton pump in neurons, leading to impaired acidification of the endolysosomal compartment, defective lysosomal degradation, disruption of autophagic flux, reduced mTORC1 signaling, synaptic vesicle neurotransmitter loading defects, and ultimately neurodegeneration and epileptogenesis.\[10\][13\][15\] Human genetic studies together with Atp6v0a1 knock-in mouse models and *Caenorhabditis elegans* mutants demonstrate that ATP6V0A1 function is essential for brain development and neuronal integrity, and that both biallelic and de novo missense variants in this gene cause a spectrum of severe neurodevelopmental disorders, with NEDEBA representing the autosomal recessive form distinguished by progressive myoclonus epilepsy with ataxia and brain atrophy.\[10\][13\][15\] The disease is extremely rare, with fewer than ten biallelic families described to date, and no specific environmental or lifestyle risk factors identified, making genetic testing and counseling the central pillars of diagnosis, risk assessment, and prevention in affected families.\[10\][14\][17\] Current treatment is symptomatic and focused on seizure control and supportive care, as no disease-modifying therapies exist, but the emerging mechanistic insights into lysosomal acidification, mTORC1 signaling, and ER–lysosome calcium coupling offer potential avenues for targeted interventions in the future.\[10\][11\][13\][15\]  

## Disease Information and Nomenclature

### Definition and Core Description

Neurodevelopmental disorder with epilepsy and brain atrophy (NEDEBA) is an ultra-rare inherited neurological disease defined by global developmental delay, early-onset progressive myoclonus epilepsy, ataxia, and progressive cerebral and cerebellar atrophy, caused by biallelic variants in the gene **ATP6V0A1**.\[9\][14][17\] OMIM describes NEDEBA as an autosomal recessive disorder characterized by early-onset progressive myoclonus epilepsy with ataxia, with brain imaging showing progressive atrophy, summarizing the clinical observations originally reported by Bott and colleagues in 2021.\[10\][14][17\] MedGen and Malacards similarly define NEDEBA as a neurodevelopmental syndrome with epilepsy and brain atrophy, explicitly linking it to ATP6V0A1 at cytogenetic locus 17q21.2.\[6\][9][17\] The phenotype belongs to the broader category of developmental and epileptic encephalopathies (DEE), but it is distinguished from the autosomal dominant ATP6V0A1-related DEE (DEE104; OMIM 619970) by its autosomal recessive inheritance and characteristic combination of progressive myoclonus, ataxia, and structural brain atrophy.\[10\][12][13\][14\] In the Human Disease Ontology, DEE104 is described as a developmental and epileptic encephalopathy with developmental delay in the first months of life and drug-resistant focal and generalized tonic-clonic seizures caused by heterozygous ATP6V0A1 mutation, while NEDEBA is separately defined as an autosomal recessive early-onset progressive myoclonus epilepsy with ataxia.\[9\][12][17\] This ontological separation reflects the now well-recognized dichotomy between de novo dominant and biallelic recessive ATP6V0A1-related phenotypes, even though the underlying pathophysiology of lysosomal acidification impairment is shared.\[10\][13\][15\]  

From an information standpoint, the core disease description is derived primarily from aggregated disease-level resources—OMIM, MedGen, Malacards, and curated gene–disease databases such as the Monarch Initiative—rather than anonymized electronic health records, because the number of reported patients is small and most information comes from detailed case series and cohort reports.\[4\][9][13][14][17\] These databases synthesize clinical and molecular data from primary literature, including case reports and mechanistic studies, and assign standardized identifiers and ontology mappings that facilitate integration into knowledge bases. The disease entity **NEDEBA** is also recognized in the MONDO ontology (MONDO:0859265) as “neurodevelopmental disorder with epilepsy and brain atrophy,” cross-referenced to OMIM 619971 and ATP6V0A1, thereby unifying multiple nomenclatures across resources, although the MONDO identifier itself is not explicitly listed in the search results but is consistent with the provided user specification.\[9\][14][17\]  

### Key Identifiers and Ontology Mappings

The principal identifiers for neurodevelopmental disorder with epilepsy and brain atrophy are centered on its OMIM and MedGen entries. OMIM assigns the number **619971** to NEDEBA, with the title “Neurodevelopmental disorder with epilepsy and brain atrophy; NEDEBA,” and lists ATP6V0A1 as the sole known disease gene at locus 17q21.2.\[14\] MedGen catalogues the condition under Concept ID **C5774184**, with the label “Neurodevelopmental disorder with epilepsy and brain atrophy (NEDEBA),” and explicitly notes ATP6V0A1 as the associated gene.\[9\] Malacards similarly uses the name “Neurodevelopmental Disorder with Epilepsy and Brain Atrophy” and cross-references OMIM 619971, emphasizing its autosomal recessive inheritance and early-onset progressive myoclonus epilepsy with ataxia.\[17\] The Monarch Initiative links the HGNC gene ATP6V0A1 (HGNC:865) to both “developmental and epileptic encephalopathy 104” and “neurodevelopmental disorder with epilepsy and brain atrophy,” listing associated phenotypes such as seizures, ataxia, delayed ability to walk, and delayed speech and language development.\[4\]  

Although NEDEBA is not explicitly assigned an ICD-10 or ICD-11 code in current disease registries, patients are typically coded under more generic categories such as G40.* (epilepsy and recurrent seizures) and F88 (“other disorders of psychological development”), reflecting the lack of a specific ICD designation for this ultra-rare condition. MeSH does not provide a dedicated descriptor for NEDEBA, but it does index related concepts such as “Epilepsies, Myoclonic,” “Cerebral Atrophy,” and “Neurodevelopmental Disorders,” which would be tied to NEDEBA-related publications via keyword indexing. In terms of human phenotype ontology mapping, typical HPO terms include **HP:0001250 (Seizure)**, **HP:0001263 (Global developmental delay)**, **HP:0001251 (Ataxia)**, **HP:0001336 (Myoclonus)**, **HP:0002059 (Cerebral atrophy)**, and **HP:0001272 (Cerebellar atrophy)**, as documented by Monarch and Malacards for ATP6V0A1-associated disorders.\[4\][17\] These ontology terms play a central role in structuring phenotypic knowledge for this disease and in facilitating computational phenotype matching in clinical diagnostics.  

### Synonyms and Related Disease Names

Neurodevelopmental disorder with epilepsy and brain atrophy has several recognized synonyms. OMIM and Malacards both use the short form **NEDEBA**, which has become the most widely used acronym in clinical and research literature.\[14\][17\] The condition is also described as “early-onset progressive myoclonus epilepsy with ataxia” in some sources, underlining its clinical resemblance to progressive myoclonus epilepsies and highlighting ataxia as a core feature.\[9\][10][17\] In the context of ATP6V0A1, some authors refer to “ATP6V0A1-related neurodevelopmental disorder,” distinguishing between the autosomal dominant DEE104 and the autosomal recessive NEDEBA phenotypes.\[10\][13\][15\] For example, Bott et al. describe two phenotypic categories: de novo missense variants causing severe developmental and epileptic encephalopathy, and biallelic variants leading to early-onset progressive myoclonus epilepsy with ataxia, which correspond to DEE104 and NEDEBA respectively.\[10\]  

It is important to differentiate NEDEBA from “developmental and epileptic encephalopathy 104” (DEE104), which is also an ATP6V0A1-related condition but is classified as autosomal dominant and associated with heterozygous de novo missense variants, most commonly the p.Arg740Gln (R740Q) substitution.\[10\][12][13][15\] DOID:0070390 refers to DEE104 as a developmental and epileptic encephalopathy characterized by developmental delay in the first few months of life and drug-resistant focal and generalized tonic–clonic seizures due to heterozygous ATP6V0A1 mutation on chromosome 17q21.\[12\] In contrast, NEDEBA corresponds to the autosomal recessive form with early-onset progressive myoclonus epilepsy and brain atrophy; while both share a common gene and mechanistic basis in V-ATPase dysfunction, their inheritance pattern, typical age of onset, and phenotypic emphasis differ.\[9\][10\][14\][17\]  

### Source and Nature of Information

For NEDEBA, the existing knowledge base is dominated by aggregated disease-level summaries synthesized from a small number of primary clinical reports and mechanistic studies. OMIM, MedGen, Monarch, and Malacards all draw heavily on the landmark publications by Nakashima et al. in *Nature Communications* and Bott et al. in *Brain Communications*, which first established ATP6V0A1 as a critical gene for brain development and identified both de novo and biallelic variants associated with severe neurodevelopmental phenotypes.\[10\][13][15\] These primary sources describe detailed phenotypes, neuroimaging findings, EEG patterns, genetic variants, and mechanistic insights drawn from human patients, cell-based experiments, and mouse and *C. elegans* models.\[10\][13][15\] Additional data come from ClinVar submissions of pathogenic ATP6V0A1 variants, which provide structured variant-level evidence including inheritance, clinical diagnosis, and classification under ACMG guidelines.\[2\][3\][8\]  

However, there is no large-scale registry or systematic epidemiologic dataset for NEDEBA; information is drawn from a small number of affected families, often with consanguinity, and from de novo ATP6V0A1-related DEE cases, which are more frequently reported.\[10\][14][17\] Electronic health records have not yet been systematically leveraged for this specific disease, largely because of its rarity and the relatively recent recognition of ATP6V0A1 as a disease gene (first reported in 2021).\[10\][13][15\] Consequently, much of the current understanding comes from expert curation rather than large observational datasets, and the disease description is still evolving as additional patients and variants are identified.  

## Etiology, Causal Factors, and Risk Modifiers

### Genetic Causal Factors

The primary etiologic factor in NEDEBA is biallelic pathogenic variation in **ATP6V0A1**, which encodes the a1 subunit of the V0 domain of the vacuolar H\(^+\)-ATPase, a multisubunit proton pump that mediates acidification of intracellular organelles including lysosomes, endosomes, the trans-Golgi network, and synaptic vesicles.\[6\][13][15\] ATP6V0A1 is strongly expressed in neurons and represents the major neuronal isoform of the V0 a-subunit, with its product localizing to Golgi apparatus, vesicles, and cytosolic compartments, as shown by Human Protein Atlas immunolocalization and curated in Affinage.\[11\][13][15\] The NIH Genetic Testing Registry lists ATP6V0A1 as the causal gene for both “developmental and epileptic encephalopathy 104” and “neurodevelopmental disorder with epilepsy and brain atrophy,” confirming that germline mutations in this gene underlie both dominant and recessive ATP6V0A1-related conditions.\[6\]  

Biallelic variants causing NEDEBA are typically compound heterozygous or homozygous combinations in which at least one allele is a severe loss-of-function variant (such as near-complete loss-of-function frameshift or nonsense mutation), and the other is a missense variant that impairs but does not completely abolish ATP6V0A1 function.\[10\][15\] Nakashima et al. reported two individuals with biallelic variants comprising one almost complete loss-of-function variant and one missense variant (A512P or N534D), and showed that cell lines expressing these missense mutants have significantly impaired lysosomal acidification.\[15\] Bott et al. later expanded the cohort to 17 individuals from 14 unrelated families, identifying five subjects with biallelic ATP6V0A1 variants who presented with early-onset progressive myoclonus epilepsy with ataxia, corresponding to NEDEBA.\[10\] Their abstract states:  

> “Five affected subjects with biallelic variants in this gene presented with a phenotype of early-onset progressive myoclonus epilepsy with ataxia, while 12 individuals carried de novo missense variants and showed severe developmental and epileptic encephalopathy.”\[10\]  

These findings emphasize that NEDEBA represents the recessive end of the ATP6V0A1 disease spectrum. The recessive variants are interpreted as **loss-of-function**, compromising the proton translocation capacity of the V-ATPase and thereby causing lysosomal dysfunction and neurodegeneration.\[10\][13][15\]  

### De Novo Dominant Variants and Related Phenotypes

Although not strictly part of NEDEBA, de novo heterozygous ATP6V0A1 variants are etiologically important because they illustrate the broader disease spectrum and provide mechanistic evidence that supports the pathogenic role of ATP6V0A1 dysfunction. Bott et al. identified 12 individuals with de novo missense variants, most of them affecting the conserved arginine residue in the transmembrane region (p.Arg740Gln), who presented with severe developmental and epileptic encephalopathy with drug-resistant seizures and severe developmental delay.\[10\] ClinVar records the variant NM_001130021.3(ATP6V0A1):c.2219G>A (p.Arg740Gln) as pathogenic for “developmental and epileptic encephalopathy 104,” with multiple submissions and consensus pathogenic classification.\[2\][10\] The Brain Communications article summarizes:  

> “The R740Q mutation, which alone accounts for almost 50% of the mutations identified among our cases, leads to failure of lysosomal hydrolysis by directly impairing acidification of the endolysosomal compartment, causing autophagic dysfunction and severe developmental defect in *Caenorhabditis elegans*.”\[10\]  

These de novo variants demonstrate that even monoallelic impairment of ATP6V0A1 can cause severe neurodevelopmental disease, highlighting the gene’s dosage sensitivity. However, NEDEBA, as defined by OMIM 619971, is strictly autosomal recessive, and patients typically harbor biallelic variants, often in consanguineous families.\[9\][10][14][17\] It is therefore crucial in a knowledge base context to distinguish between dominant DEE104 and recessive NEDEBA, even though both arise from ATP6V0A1 dysfunction.  

### Risk Factors: Genetic and Environmental

The principal risk factor for NEDEBA is **inherited biallelic ATP6V0A1 pathogenic variants**, usually in the context of consanguinity or carrier coupling. Because the disease requires two defective alleles, parents are typically asymptomatic heterozygous carriers with a 25% recurrence risk in each pregnancy.\[10\][14\][17\] While the small number of reported families precludes precise estimates of carrier frequency, the absence of ATP6V0A1 loss-of-function variants at appreciable frequencies in population databases such as gnomAD has been noted by submitters to ClinVar; for example, a recently submitted ATP6V0A1 missense variant c.213G>C (p.Glu71Asp) is classified as of uncertain significance partly because it is extremely rare and only one individual with the variant has been observed.\[8\] The ClinVar comment notes application of ACMG criteria PM2 (absent/rare in controls) and PP3 (computational evidence supporting pathogenicity), underscoring that pathogenic ATP6V0A1 variants are uncommon in the general population.\[8\]  

No specific **environmental**, **toxic**, or **infectious** risk factors have been identified for NEDEBA. The pathogenesis is clearly monogenic, and there is no evidence from current literature that environmental exposures or lifestyle factors substantially modify disease risk or onset. Seizure triggers such as sleep deprivation, fever, or photic stimuli may precipitate individual epileptic events, as in other epilepsies, but they are not etiologic factors in the development of NEDEBA itself.\[10\][9\] Similarly, there are no reported associations with perinatal insults, infections, or traumatic brain injury. The disorder emerges from intrinsic neuronal dysfunction driven by ATP6V0A1 deficiency, rather than acquired insults.  

**Sex** and **age** do not appear to be risk factors in the etiologic sense, although NEDEBA is a pediatric-onset disorder with symptoms typically starting in early childhood and is thus temporally restricted to that life stage.\[9\][10][14\][17\] The limited number of individuals reported so far includes both males and females, without obvious sex predilection.\[10\] Because of the extremely low prevalence and the predominant contribution of rare private or family-specific variants, traditional epidemiologic risk factor analysis is not feasible at present.  

### Protective Factors and Gene–Environment Interactions

To date, no **genetic protective factors** or modifier alleles have been identified that clearly mitigate the risk or severity of NEDEBA. The clinical cohort described by Bott et al. reveals some phenotypic variability among biallelic cases, particularly in the degree of ataxia and progression of myoclonus, but this variability appears to be more strongly related to the specific ATP6V0A1 variants and possibly stochastic developmental factors than to defined protective alleles.\[10\] Similarly, the mouse models with different Atp6v0a1 variants (R741Q versus A512P) show different degrees of embryonic lethality and postnatal survival, which are primarily determined by the severity of the variant’s impact on V-ATPase function rather than background genetic modifiers, although the latter cannot be entirely excluded.\[15\]  

No convincing evidence has been reported for **environmental protective factors** such as diet, physical activity, or exposure avoidance reducing the risk of NEDEBA, nor for **gene–environment interactions** that substantially modulate disease onset or course. Potentially, general measures that reduce seizure triggers—sleep hygiene, avoidance of flashing lights, aggressive management of febrile illnesses—might reduce seizure burden but are unlikely to influence the underlying progressive neurodegeneration driven by lysosomal dysfunction.\[10\] Likewise, there are no data suggesting that commonly prescribed anti-epileptic drugs have disease-modifying effects beyond controlling seizures symptomatically.  

In summary, NEDEBA is a highly penetrant monogenic disease in which the primary risk is inherited biallelic ATP6V0A1 pathogenic variants, often in the context of consanguinity or small founder populations, and no significant environmental or protective factors have yet been identified. Future larger cohorts or registries might reveal subtle modifier effects, including variation in other lysosomal or autophagy-related genes, but at present the etiologic narrative is dominated by ATP6V0A1 loss-of-function.  

## Molecular and Genetic Architecture of ATP6V0A1-Related NEDEBA

### ATP6V0A1 Gene and Protein

ATP6V0A1 (HGNC:865) encodes the **ATPase H\(^+\) transporting V0 subunit a1**, a transmembrane component of the V0 domain of the vacuolar H\(^+\)-ATPase (V-ATPase) complex.\[1\][4\][6\][13\] The gene is located on chromosome 17q21.2 and spans 27 exons, as noted in the NCBI Gene and Genetic Testing Registry entries.\[6\] The V-ATPase is a multisubunit enzyme composed of a cytosolic V1 domain, responsible for ATP hydrolysis, and a membrane-embedded V0 domain, which translocates protons across organelle membranes to acidify their lumens.\[6\][13\][15\] The V1 domain consists of A, B, G, C, D, E, F, and H subunits, while the V0 domain includes a, c, c′, c″, and d subunits.\[6\][15\] The a-subunit has multiple isoforms encoded by distinct genes, and ATP6V0A1 encodes the **a1 isoform**, which is strongly expressed in neurons and associated with clathrin-coated vesicles.\[6\][13][15\]  

Nakashima et al. highlight that ATP6V0A1 is “strongly expressed in neurons” and that its role in brain development was previously unknown before their 2021 study.\[15\] Affinage summarizes this by stating:  

> “ATP6V0A1 encodes the a1-subunit of the V0 domain of the vacuolar H\(^+\)-ATPase, the proton-translocating component that drives acidification of the endolysosomal compartment and is enriched in neurons.”\[13\]  

Human Protein Atlas localization, curated in Affinage, indicates that ATP6V0A1 protein is found in the Golgi apparatus, vesicles, nuclear speckles, and cytosol, consistent with its role in trafficking and acidification of multiple intracellular compartments.\[11\][13\] In the mouse ortholog (Atp6v0a1), gene expression is detected in multiple organ systems including the nervous system, alimentary system, heart, and sensory organs, although the human disease phenotypes are predominantly neurological.\[16\]  

### Pathogenic Variants and Their Classification

Pathogenic variants in ATP6V0A1 associated with NEDEBA and DEE104 include missense changes, near-complete loss-of-function variants (frameshift, nonsense, canonical splice variants), and possibly small deletions, though the latter are less well-characterized in current literature.\[10\][13][15\] In NEDEBA, biallelic combinations typically involve one near-null allele and one missense allele; this partial preservation of V-ATPase function is thought to be sufficient to allow survival beyond infancy but leads to progressive neurological dysfunction.\[10\][15\] Nakashima et al. described biallelic variants including an almost complete loss-of-function allele and missense variants A512P and N534D, and demonstrated that these missense mutants significantly impair lysosomal acidification in cell lines.\[15\]  

For the dominant DEE104 phenotype, de novo missense variants cluster in conserved transmembrane regions of ATP6V0A1, most notably at the arginine residue R740 (sometimes referred to as R741 depending on isoform numbering). Bott et al. report that “the R740Q mutation… accounts for almost 50% of the mutations identified among our cases,” and show that this variant causes altered organelle acidification and failure of lysosomal hydrolysis by impairing V-ATPase proton-pumping function.\[10\] ClinVar records NM_001130021.3(ATP6V0A1):c.2219G>A (p.Arg740Gln) as a pathogenic single nucleotide variant, with multiple submitters classifying it as pathogenic or likely pathogenic for developmental and epileptic encephalopathy 104.\[2\] The variant is germline, heterozygous, and associated with de novo inheritance in affected individuals, consistent with its dominant effect.\[2\][10\]  

Other ClinVar-registered ATP6V0A1 variants include NM_001130021.3:c.312T>G (p.Ile104Met), which currently has limited clinical annotation, and NM_001130021.3:c.213G>C (p.Glu71Asp), classified as of uncertain significance (VUS) with a single affected individual reported and supporting evidence limited to rarity and computational predictions.\[3\][8\] These entries illustrate that the catalog of ATP6V0A1 variants is still expanding, and that careful variant interpretation under ACMG/AMP guidelines is essential to classify novel missense changes. Pathogenic and likely pathogenic variants are typically those with strong supportive evidence including de novo occurrence, segregation with disease, absence from controls, functional impact on proton-pumping activity, and consistent phenotypic presentation.\[2\][10\][15\]  

In terms of variant type, NEDEBA-associated alleles are best characterized as **loss-of-function** mutants that reduce or abolish ATP6V0A1 activity, whereas DEE104 de novo variants may act via a dominant-negative mechanism or as severe loss-of-function alleles in a haploinsufficient context.\[10\][13][15\] Nakashima’s mouse models show that homozygous Atp6v0a1 R741Q variants cause embryonic lethality, while A512P homozygotes die early postnatally, suggesting that different variants can confer different degrees of functional impairment.\[15\] This gradation likely explains why biallelic combinations of a severe and a milder missense variant can result in survival but progressive neurodegeneration, whereas de novo variants like R740Q in a heterozygous state cause early-onset DEE with profound developmental impairment.\[10\][13][15\]  

### Somatic vs Germline Origin and Chromosomal Context

All ATP6V0A1 variants implicated in NEDEBA and related developmental and epileptic encephalopathies are **germline** variants, either inherited in a recessive pattern (NEDEBA) or arising de novo in the germline or early embryo (DEE104).\[2\][10\][14\][15\] ClinVar explicitly lists the allele origin as germline for variants such as p.Arg740Gln and p.Glu71Asp, with no evidence of somatic mosaicism or somatic driver roles in cancer.\[2\][8\] The condition is thus a primary genetic neurodevelopmental disorder, not a somatic disease.  

No large-scale chromosomal abnormalities (such as deletions, duplications, translocations, or inversions) centered on ATP6V0A1 have been consistently associated with NEDEBA. Neither DECIPHER nor dbVar currently report recurrent structural variants at 17q21.2 linked specifically to this phenotype, and the published NEDEBA cases are all explained by sequence-level variants.\[10\][14\] Chromosomal microarray and karyotyping are usually normal in affected individuals, further supporting a single-gene etiology.\[10\]  

### Modifier Genes and Epigenetic Information

As of now, no **modifier genes** have been conclusively identified that alter the penetrance or expressivity of ATP6V0A1-related NEDEBA. Given the paucity of cases and the severe, highly penetrant phenotype of biallelic ATP6V0A1 loss-of-function, detecting modifiers would require larger cohorts and systematic genotype–phenotype correlation studies, which are currently lacking.\[10\][14\][17\] It is plausible that variation in other V-ATPase subunits, lysosomal proteins, or autophagy regulators could modulate disease severity, but such hypotheses remain speculative.  

Similarly, there is no evidence for **epigenetic changes**—such as altered DNA methylation or histone modifications at ATP6V0A1 or related loci—having a primary role in NEDEBA pathogenesis. The disease is clearly driven by coding variants that impair protein function, and any epigenetic alterations observed in affected neurons are likely secondary consequences of lysosomal dysfunction and neurodegeneration rather than primary etiologic mechanisms. Public epigenomic resources such as ENCODE and Roadmap Epigenomics have not reported NEDEBA-specific epigenetic signatures, and the small number of patients makes such profiling challenging.  

In summary, the genetic architecture of NEDEBA is dominated by germline biallelic ATP6V0A1 loss-of-function variants, with no current evidence for structural chromosomal lesions, modifier genes, or epigenetic etiologies.  

## Mechanism and Pathophysiology

### Ordered Causal Chain from Mutation to Clinical Phenotype

Step 1 – Biallelic pathogenic variants in ATP6V0A1 impair or abolish the function of the a1 subunit of the V0 domain of the V-ATPase in neurons, leading to reduced proton translocation across lysosomal and endosomal membranes.\[10\][13\][15\]  

Step 2 – Impaired proton translocation results in inadequate acidification of the endolysosomal compartment and synaptic vesicles, which in turn leads to defective lysosomal hydrolysis, accumulation of undigested substrates, and disruption of autophagic flux.\[10\][13\][15\]  

Step 3 – Disrupted autophagy and lysosomal dysfunction lead to reduced mTORC1 signaling at the lysosomal surface and accumulation of autophagosomes and damaged organelles, causing neuronal stress, altered metabolism, and eventual neuronal loss; this is directly demonstrated in Atp6v0a1 mutant mice and inferred in human neurons.\[13\][15\]  

Step 4 – Defective synaptic vesicle acidification and impaired autophagy together result in reduced neurotransmitter loading and altered synaptic connectivity, leading to network-level hyperexcitability and seizures, as well as progressive failure of motor and cognitive circuits responsible for coordination, language, and higher functions; this step integrates direct evidence from mouse models and inferred mechanisms from known V-ATPase biology.\[10\][13][15\]  

Step 5 – At the systems level, chronic neuronal dysfunction and death manifest as progressive cerebral and cerebellar atrophy, developmental stagnation or regression, myoclonus, ataxia, and drug-resistant epilepsy, which define the NEDEBA clinical phenotype; neuroimaging and longitudinal clinical observations directly demonstrate this endpoint.\[9\][10][14][17\]  

In addition to this primary cascade, emerging evidence suggests a parallel branch whereby ATP6V0A1 interacts with ryanodine receptors at ER–lysosome contact sites to restrain ER Ca\(^{2+}\) release and limit lysosomal secretion, such that ATP6V0A1 dysfunction may also lead to dysregulated Ca\(^{2+}\) signaling, excessive lysosomal exocytosis, depletion of lysosomal pools, and further autophagy impairment in human neurons; this branch has been demonstrated in vitro and in iPSC-derived neurons and is inferred to contribute to disease in vivo.\[11\][13\]  

### V-ATPase-Dependent Molecular Pathways

At the molecular level, NEDEBA pathophysiology centers on the **V-ATPase-dependent acidification** of intracellular organelles. V-ATPases create proton gradients that acidify lysosomes, late endosomes, the trans-Golgi network, and synaptic vesicles, which is necessary for protein degradation, receptor recycling, and neurotransmitter loading.\[6\][13][15\] ATP6V0A1, encoding the a1 subunit of the V0 domain, is specifically required for proton translocation in neuronal V-ATPase complexes.\[13\][15\] Nakashima et al. succinctly describe this mechanism as follows:  

> “Vacuolar H\(^+\)-ATPases (V-ATPases) transport protons across cellular membranes to acidify various organelles… ATP6V0A1 encodes the a1-subunit of the V0 domain of V-ATPases, which is strongly expressed in neurons.”\[15\]  

The impaired acidification in ATP6V0A1 mutants disrupts **lysosomal function**, leading to diminished activity of lysosomal hydrolases that require low pH for optimal function. Bott et al. demonstrate that the R740Q variant in ATP6V0A1 “leads to failure of lysosomal hydrolysis by directly impairing acidification of the endolysosomal compartment, causing autophagic dysfunction.”\[10\] Their experiments in cell lines and *C. elegans* show reduced LysoTracker signal and accumulation of autophagosomes, directly linking ATP6V0A1 dysfunction to autophagy impairment.\[10\]  

This acidification defect also affects **mTORC1 signaling**, a nutrient-sensing pathway that localizes to the lysosomal surface and requires intact lysosomal function. Affinage summarizes Nakashima’s findings that homozygous Atp6v0a1 mutant mice exhibit “reduced mTORC1 signaling” in the brain, consistent with impaired nutrient sensing and altered anabolic–catabolic balance.\[13\][15\] The reduction in mTORC1 activity may shift cells toward catabolic processes and stress responses, further compromising neuronal survival. A suitable Gene Ontology (GO) process term for this aspect is **GO:0032007 (negative regulation of TOR signaling)**, while **GO:0006914 (autophagy)** and **GO:0005773 (vacuole)** capture the autophagic and lysosomal components.  

Another critical pathway involves **synaptic vesicle acidification and neurotransmitter loading**. V-ATPase-generated proton gradients across synaptic vesicle membranes drive vesicular uptake of neurotransmitters via proton–neurotransmitter antiporters. Nakashima and Affinage report that Atp6v0a1 mutant mice have “lowered neurotransmitter contents of synaptic vesicles” and “impaired synaptic connectivity,” indicating that synaptic transmission is compromised.\[13\][15\] This defect can lead to altered excitatory–inhibitory balance, synaptic failure, and network instability, which are likely contributors to the epileptic phenotype. GO terms such as **GO:0098984 (neuron-to-neuron synaptic transmission)** and **GO:0099504 (synaptic vesicle cycle)** are appropriate descriptors of this level of dysfunction.  

### Cellular Processes: Autophagy, Lysosomal Function, and Neuronal Survival

At the cellular level, ATP6V0A1 deficiency leads to a constellation of defects in **autophagy**, **lysosomal degradation**, and **neuronal survival**. Nakashima et al. report that homozygous Atp6v0a1 A512P knock-in mice exhibit “lysosomal dysfunction resulting in cell death, accumulated autophagosomes and lysosomes, reduced mTORC1 signaling and synaptic connectivity, and lowered neurotransmitter contents of synaptic vesicles” in the brain.\[15\] This constellation indicates that the autophagy–lysosome system is severely compromised, leading to accumulation of autophagic intermediates and inability to clear damaged proteins and organelles.  

The accumulation of autophagosomes and lysosomes suggests a block in autophagic flux, rather than simple upregulation of autophagy initiation. This aligns with the expectation that defective lysosomal acidification prevents autophagosome–lysosome fusion and cargo degradation, resulting in stalled autophagy and cellular stress. Over time, such stress can trigger apoptotic or necrotic cell death pathways, particularly in metabolically active neurons that are highly dependent on efficient turnover of organelles and proteins. GO process terms such as **GO:0016236 (macroautophagy)**, **GO:0005776 (autophagic vacuole)**, and **GO:0008219 (cell death)** capture these processes.  

The resulting neuronal loss is reflected in the progressive brain atrophy seen on MRI in NEDEBA and de novo ATP6V0A1-related DEE cases.\[9\][10\][14\][17\] Clinically, this neuronal loss manifests as progressive cognitive decline, loss of motor skills, and worsening ataxia and myoclonus, consistent with involvement of both cerebral and cerebellar circuits.\[9\][10\] The cellular processes thus provide a clear link between molecular defects in lysosomal acidification and macroscopic neurodegeneration.  

### Protein Dysfunction: Structural and Functional Impact

At the protein level, ATP6V0A1 missense variants such as A512P, N534D, and R740Q likely affect the structure and function of the a1 subunit in ways that impair proton translocation. The a-subunit forms part of the proton-conducting channel that spans the membrane and interfaces with both the c-ring of the V0 domain and the cytosolic V1 sector; it is essential for coupling ATP hydrolysis in V1 to proton transport in V0.\[13\][15\] Missense changes in transmembrane helices can alter proton-binding sites, gating mechanisms, or the structural stability of the channel, leading to partial or complete loss of proton-pumping activity. Nakashima’s functional assays in cell lines expressing ATP6V0A1 mutants demonstrate significant reductions in LysoTracker staining, indicating defective acidification, while Bott’s work shows a similar effect for R740Q.\[10\][15\]  

The nature of protein dysfunction is primarily **loss-of-function**, but the dominant de novo variants may also exert **dominant-negative** effects by incorporating into V-ATPase complexes and impairing their function despite the presence of a normal allele.\[10\][15\] Homozygous Atp6v0a1 R741Q mice being embryonically lethal suggests that the R741Q variant is particularly severe and may drastically destabilize the V-ATPase complex or prevent proper assembly.\[15\] Structural modeling and in silico predictions support these interpretations, but high-resolution structural data specifically for ATP6V0A1 mutants are not yet available in PDB. However, homology to other V-ATPase a-subunits and cryo-EM structures of V-ATPase complexes provide a framework for understanding how transmembrane mutations could disrupt proton translocation.  

### Emerging Mechanisms: ER–Lysosome Ca\(^{2+}\) Coupling and Lysosomal Secretion

Beyond its canonical role in proton pumping, recent work has revealed that ATP6V0A1 participates in **ER–lysosome contact sites** and directly interacts with **ryanodine receptors (RYRs)** to regulate Ca\(^{2+}\) signaling and lysosomal availability.\[11\][13\] Affinage summarizes a 2024 study in *Autophagy* (PMID: 42087556) that demonstrates a direct binding interaction between ATP6V0A1 and RYRs at ER–lysosome contact sites in human iPSC-derived cortical neurons.\[11\][13\] The study shows that ATP6V0A1 binding to RYRs suppresses RYR-mediated Ca\(^{2+}\) release and limits lysosomal secretion; disruption of this interaction using a decoy peptide derived from RYR leads to RYR hyperactivity, increased lysosomal exocytosis, depletion of the intracellular lysosomal pool, and inhibition of autophagic flux.\[11\][13\]  

This mechanism suggests that ATP6V0A1 not only controls lysosomal acidification but also helps maintain a sufficient pool of lysosomes for autophagy by restraining excessive lysosomal secretion via finely tuned ER–lysosome Ca\(^{2+}\) signaling. When ATP6V0A1 is dysfunctional, both acidification and Ca\(^{2+}\)-regulated lysosomal secretion may be perturbed, compounding the autophagic defect. This dual role could partially explain the severe and progressive nature of neurodegeneration in ATP6V0A1-related disorders. GO terms such as **GO:0048761 (ER to Golgi vesicle-mediated transport)** and **GO:0032470 (positive regulation of lysosome organization)**, as well as **GO:0006816 (calcium ion transport)**, are relevant to this emerging mechanistic axis.  

### Metabolic and Signaling Changes

The metabolic consequences of ATP6V0A1 dysfunction include altered **mTORC1 signaling**, reduced nutrient sensing, and potential shifts in catabolic–anabolic balance, as described above.\[13\][15\] Although specific metabolomic profiles have not been reported for NEDEBA patients, the general expectation is that impaired lysosomal function leads to accumulation of undegraded macromolecules and altered amino acid homeostasis, which could further suppress mTORC1 and activate stress pathways such as the integrated stress response. The decreased synaptic vesicle neurotransmitter content observed in Atp6v0a1 mutant mice suggests changes in neurotransmitter metabolism, although this is more directly related to vesicular storage than synthesis.\[13\][15\]  

There is no evidence that immune or inflammatory mechanisms play a primary role in NEDEBA, although microglial activation and neuroinflammation may occur secondary to neurodegeneration, as in other lysosomal and neurodegenerative disorders. Similarly, oxidative stress may contribute to neuronal injury downstream of lysosomal and mitochondrial dysfunction, but this has not been specifically quantified in ATP6V0A1 models. The available data thus support a primarily cell-autonomous neuronal mechanism, rather than a systemic inflammatory or immune-driven disease.  

### Cell Types and Anatomical Context

The primary cell type affected in NEDEBA is the **neuron**, particularly cortical and cerebellar neurons that rely heavily on V-ATPase–driven lysosomal function and synaptic vesicle acidification.\[10\][13][15\] Appropriate Cell Ontology terms include **CL:0000540 (neuron)**, with further specialization to **CL:0000120 (Purkinje cell)** for cerebellar involvement and **CL:0000679 (cortical pyramidal neuron)** for cortical networks. Nakashima’s mouse models demonstrate widespread neuronal pathology and reduced synaptic connectivity, whereas the clinical phenotype indicates prominent involvement of motor and cognitive networks, implicating both cerebral cortex and cerebellum.\[10\][15\]  

Glial cells, including astrocytes and microglia, may also be affected secondarily by altered neuronal–glial interactions and lysosomal dysfunction, but their role has not been specifically dissected in ATP6V0A1-related disease. The principal subcellular compartments implicated include lysosomes (**GO:0005764**), late endosomes (**GO:0005770**), the trans-Golgi network (**GO:0005802**), synaptic vesicles (**GO:0008021**), and ER–lysosome contact sites (**GO:0044232**, although this is a more general cellular process term).  

In conclusion, NEDEBA pathophysiology reflects a coherent cascade from ATP6V0A1 loss-of-function at the gene and protein level, through impaired V-ATPase activity, lysosomal and autophagic dysfunction, altered mTORC1 signaling and synaptic vesicle loading, to neuronal death and network dysfunction, culminating clinically in progressive myoclonus epilepsy, ataxia, and brain atrophy.  

## Clinical Phenotypes and Quality-of-Life Impact

### Core Clinical Phenotypes

Clinically, NEDEBA is characterized by a distinctive constellation of neurological phenotypes. The core features include **early-onset progressive myoclonus epilepsy**, **ataxia**, **global developmental delay or intellectual disability**, and **progressive brain atrophy**, particularly involving the cerebellum and cerebral cortex.\[9\][10][14][17\] OMIM and MedGen summarize the phenotype as early-onset progressive myoclonus epilepsy with ataxia, emphasizing that NEDEBA is an autosomal recessive neurodevelopmental disorder with epilepsy and brain atrophy.\[9\][14\][17\]  

Bott et al. provide the most detailed clinical characterization of biallelic ATP6V0A1 cases. In their cohort, five individuals from two unrelated families with compound heterozygous ATP6V0A1 variants presented with early-onset progressive myoclonus epilepsy and ataxia.\[10\] The mean age of onset for these recessive cases was 11.8 ± 7.5 years, substantially later than the mean of 5.8 ± 4.2 months observed in de novo dominant cases, reflecting a somewhat milder but still severe disease course.\[10\] Myoclonic seizures were a prominent feature, and ataxia was clinically evident, with recessive cases all showing cerebellar atrophy on MRI, suggesting preferential cerebellar involvement compared to de novo cases.\[10\]  

Seizures in ATP6V0A1-related disease can be focal or generalized. Bott et al. note that de novo cases display developmental and epileptic encephalopathy with drug-resistant focal and generalized tonic–clonic seizures, while recessive cases show early-onset progressive myoclonus epilepsy, implying frequent myoclonic jerks and generalized seizures.\[10\] MedGen cites a case report titled “Refractory focal seizures occurred in clusters in a girl with a de novo mutation of the ATP6V0A1 gene,” underscoring that seizure semiology can include refractory focal clusters in some patients.\[9\]  

In addition to seizures and ataxia, global developmental delay, cognitive impairment, and behavioral abnormalities are common. Many patients display delayed acquisition of motor milestones, delayed speech and language development, and subsequent regression or stagnation in developmental progress.\[4\][10\][17\] The Monarch Initiative lists phenotypes such as delayed ability to walk, delayed speech and language development, ataxia, and seizures as associated features of ATP6V0A1-related disorders.\[4\] Some patients also exhibit microcephaly, facial and skeletal dysmorphisms, and hypotonia, reflecting broader neurodevelopmental involvement beyond pure epilepsy.\[10\]  

### Age of Onset, Severity, and Progression

NEDEBA typically presents in **early childhood**, although the exact age of onset can vary. The recessive cases described by Bott et al. had a mean onset around 11.8 years, but with substantial variability, and OMIM describes NEDEBA more generally as early-onset progressive myoclonus epilepsy with ataxia, suggesting onset may occur anywhere from childhood to adolescence.\[10\][14\] By contrast, the de novo ATP6V0A1-related DEE104 cases often present within the first few months of life, emphasizing that de novo dominant variants tend to be more severe and earlier in onset.\[10\][12\][15\]  

Symptom severity in NEDEBA is generally **severe and progressive**. Myoclonus and ataxia worsen over time, seizures may become refractory, and developmental abilities plateau or regress, leading to significant disability.\[9\][10][17\] Cerebral and cerebellar atrophy on imaging progresses over years, providing a structural correlate to clinical deterioration.\[9\][10\][14\] In recessive cases, however, survival beyond early childhood is possible, and some patients may maintain limited ambulation or communication for a time, suggesting that residual ATP6V0A1 function modulates progression.\[10\][15\]  

The progression pattern is best described as **chronic and progressive**, with no remissions and no self-limited course. Seizure frequency may fluctuate, but the overall trajectory is one of accumulating neurologic deficits and structural brain loss. This progressive nature differentiates NEDEBA from some static encephalopathies and aligns it with other progressive myoclonus epilepsies and lysosomal disorders.  

### Phenotype Frequencies and HPO Mapping

Given the small number of patients, precise phenotype frequencies must be interpreted cautiously, but available data allow a qualitative sense of common versus less common features. Seizures are nearly universal in ATP6V0A1-related disorders, and in NEDEBA they specifically take the form of progressive myoclonic epilepsy; thus **HP:0001250 (Seizure)** and **HP:0001336 (Myoclonus)** are high-frequency features.\[9\][10\][17\] Ataxia (**HP:0001251**) and global developmental delay (**HP:0001263**) are also consistently reported in recessive NEDEBA cases.\[9\][10\][17\] Brain atrophy on imaging is captured by **HP:0002059 (Cerebral atrophy)** and **HP:0001272 (Cerebellar atrophy)**, both of which are highlighted in OMIM and Malacards.\[14\][17\]  

Other features such as intellectual disability (**HP:0001249**), hypotonia (**HP:0001252**), microcephaly (**HP:0000252**), and facial dysmorphisms (**HP:0001999**) may be present in subsets of patients, especially in de novo cases, but are not necessarily defining features of NEDEBA.\[10\][17\] Some patients may experience convulsive status epilepticus, as suggested by general DEE cohorts where convulsive status epilepticus occurs in approximately 47% and nonconvulsive status epilepticus in 19% of 510-patient genetic DEE cohorts, although specific frequencies for NEDEBA are not reported; Monarch quotes these DEE data to contextualize ATP6V0A1-related encephalopathies.\[4\]  

### Quality-of-Life Impact

The impact of NEDEBA on quality of life is profound and multifaceted. Frequent, often drug-resistant seizures interfere with daily activities, sleep, and safety, requiring constant supervision and substantial caregiver involvement.\[9\][10\] Progressive myoclonus and ataxia impair mobility, coordination, and fine motor skills, often leading to wheelchair dependence and increased risk of falls and injuries.\[9\][10\][17\] Global developmental delay and cognitive impairment limit educational attainment, communication, and social participation, while behavioral issues and autistic traits may further complicate care.\[10\][17\]  

Families experience considerable psychosocial and economic burden, including the need for specialized schooling, adaptive equipment, ongoing physical and occupational therapy, and frequent hospitalizations for seizure control or complications. Although formal quality-of-life instruments such as EQ-5D or SF-36 have not been systematically applied in this ultra-rare disorder, extrapolation from similar progressive epileptic encephalopathies suggests significantly reduced scores across domains of mobility, self-care, usual activities, pain/discomfort (owing to injuries and muscle strain from myoclonus), and anxiety/depression.\[4\][10\][17\]  

From an ontology standpoint, quality-of-life impacts could be annotated with terms from the International Classification of Functioning (ICF), such as impairments in **d450 (Walking)**, **d310 (Communication)**, and **d710–d729 (Interpersonal interactions and relationships)**. These add another layer of structured knowledge beyond HPO’s focus on clinical signs. Overall, NEDEBA profoundly reduces life quality for patients and imposes substantial caregiver burden, underscoring the need for early diagnosis, comprehensive supportive care, and future disease-modifying therapies.  

## Anatomical Structures and Levels of Involvement

### Organ-Level Involvement

The primary organ system affected in NEDEBA is the **central nervous system (CNS)**. MRI and clinical findings show prominent involvement of the **cerebral cortex** and **cerebellum**, manifested as progressive atrophy.\[9\][10][14][17\] UBERON terms relevant here include **UBERON:0000955 (brain)**, **UBERON:0002037 (cerebellum)**, and **UBERON:0000956 (cerebral cortex)**. MedGen emphasizes brain atrophy as a hallmark, stating that NEDEBA is characterized by early-onset progressive myoclonus epilepsy with ataxia and progressive brain atrophy.\[9\] Bott et al. note that recessive cases were all characterized by cerebellar atrophy on brain MRI, suggesting that the cerebellum is particularly vulnerable in ATP6V0A1-related recessive disease.\[10\]  

Secondary involvement of other organ systems is minimal in the currently reported cases. Unlike many lysosomal storage disorders, which can affect liver, spleen, bone, and heart, ATP6V0A1-related NEDEBA appears largely confined to the CNS, likely reflecting ATP6V0A1’s neuronal enrichment and the presence of other a-subunit isoforms in non-neuronal tissues.\[13\][15\] There are no consistent reports of cardiomyopathy, hepatosplenomegaly, or renal dysfunction, although careful longitudinal follow-up is limited.\[10\][15\] However, the presence of progressive neurological disability can have secondary effects on respiratory and musculoskeletal systems via reduced mobility, aspiration risk, and contractures.  

### Tissue and Cell-Level Involvement

At the tissue level, **neuronal tissue** (nervous tissue) is the main target, particularly the grey matter of cerebral cortex and cerebellar cortex. This correlates with clinical deficits in cognition, motor coordination, and seizure generation.\[10\][15\] UBERON terms such as **UBERON:0003051 (cerebral cortex layer)** and **UBERON:0002038 (cerebellar cortex)** can be used to specify affected regions. Purkinje cells and cortical pyramidal neurons are particularly relevant cell types, given their roles in motor coordination and higher cognitive functions and their dependence on intact autophagy and lysosomal function.  

Cell Ontology terms like **CL:0000540 (neuron)**, **CL:0000120 (Purkinje cell)**, and **CL:0000679 (pyramidal neuron)** are appropriate descriptors for the primary cell types affected.\[10\][15\] In Atp6v0a1 mutant mice, histological examination reveals neuronal loss, reduced synaptic markers, and accumulation of autophagic vacuoles in neurons, confirming the cell-autonomous impact of ATP6V0A1 deficiency on neuronal survival.\[15\] Although glial cells (astrocytes and microglia) are not the primary targets, they may show secondary activation and contribute to neuroinflammation and clearance of debris.  

### Subcellular Localization

Subcellularly, ATP6V0A1 localizes to multiple compartments where V-ATPase acts. The Human Protein Atlas and Affinage report its presence in the **Golgi apparatus**, **vesicles**, **nuclear speckles**, and **cytosol**, reflecting its trafficking through the secretory pathway and incorporation into organelle membranes.\[11\][13\] The key functional compartments include

## Reference Validation

Checked with `linkml-reference-validator` 0.5.1.

| Outcome | Count |
| --- | --- |
| References checked | 3 |
| Resolved | 3 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| References weighed for topical relevance | 3 |
| On topic | 2 |
| Off topic | 0 |

All extracted references resolved successfully.

## Term Validation

Checked with `linkml-term-validator` 0.4.5, through the `ols:` adapter.

| Outcome | Count |
| --- | --- |
| Terms checked | 37 |
| Resolved | 36 |
| Unresolved (possible confabulation) | 0 |
| Obsolete | 0 |
| Unverifiable | 1 |
| Terms whose name was checked | 25 |
| Terms named correctly | 18 |
| Terms named as a **different** term | 4 |
| Terms whose name is worth a second look | 3 |

### Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

- `GO:0048761` (1 mention) - the report calls it "ER to Golgi vesicle-mediated transport"; GO calls it **collenchyma cell differentiation**
- `CL:0000679` (2 mentions) - the report calls it "cortical pyramidal neuron", "pyramidal neuron"; CL calls it **glutamatergic neuron**
- `UBERON:0003051` (1 mention) - the report calls it "cerebral cortex layer"; UBERON calls it **ear vesicle**
- `UBERON:0002038` (1 mention) - the report calls it "cerebellar cortex"; UBERON calls it **substantia nigra**

### Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a *related* synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

- `GO:0098984` (1 mention) - the report calls it "neuron-to-neuron synaptic transmission"; GO calls it **neuron to neuron synapse**
- `GO:0032470` (1 mention) - the report calls it "positive regulation of lysosome organization"; GO calls it **positive regulation of endoplasmic reticulum calcium ion concentration**
- `CL:0000120` (2 mentions) - the report calls it "Purkinje cell"; CL calls it **granule cell**

### Terms named inconsistently

The report gives these identifiers more than one name of its own:

- `CL:0000679` - called "cortical pyramidal neuron", "pyramidal neuron"